Microcap Ledger Kairos Pharma, LTD. $KAPA
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- NYSE American
- Sector
- Pharmaceutical Preparations
- Headquarters
- Los Angeles, CA
- Fiscal year end
- December 31
- Shares outstanding
- 23,697,683 [10-Q 2026-08-12]
What the company doesAI summary of filing
Kairos Pharma is a clinical-stage biopharmaceutical company developing therapeutics for cancer patients. The company's portfolio consists of seven drug candidates in preclinical or clinical-trial stages, including small molecules and antibodies targeting immune suppression and drug resistance in prostate cancer, lung cancer, breast cancer, and glioblastoma. The company has not yet generated product revenue, as none of its candidates have received FDA approval. Kairos makes money through development and commercialization of these therapeutic candidates, with ENV 105 and KROS 201 currently in clinical trials and other candidates in earlier development stages. [10-K 2026-03-31]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$3.04M | −$2.05M | $2.63M | [10-Q 2026-08-12] |
| FY ended Dec 2025 | — | −$5.45M | −$3.44M | $4.49M | [10-K 2026-03-31] |
| FY ended Dec 2024 | — | −$2.60M | −$3.96M | $1.27M | [10-K 2026-03-31] |
- Quarterly cash burn
- −$1.02M
- Cash runway Estimate
- ~7.7 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2025-04-14 | 16,693,306 | [10-K/A 2025-04-29] |
| 2025-05-13 | 16,849,306 | [10-Q 2025-05-14] |
| 2025-07-28 | 20,457,480 | [10-K/A 2025-07-28] |
| 2025-08-11 | 20,743,765 | [10-Q 2025-08-12] |
| 2025-11-14 | 20,821,353 | [10-Q 2025-11-14] |
| 2026-03-31 | 21,411,198 | [10-K 2026-03-31] |
| 2026-05-11 | 21,411,198 | [10-Q 2026-05-13] |
| 2026-08-12 | 23,697,683 | [10-Q 2026-08-12] |
- Shelf registration
- S-3 filed 2026-01-13; declared effective 2026-01-23 [S-3 2026-01-13]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2025-10-08 | Bhowmick Neil | grant | 171,756 | — | [4 2025-12-30] |
| 2025-10-08 | Bae Hyun W. | grant | 19,084 | — | [4 2025-12-23] |
| 2025-10-08 | Murali Ramachandran | grant | 152,672 | — | [4 2025-11-26] |
| 2025-10-08 | Keyoung Hansoo Michael | grant | 19,084 | — | [4 2025-11-26] |
| 2025-10-08 | Singhvi Rahul | grant | 19,084 | — | [4 2025-11-26] |
| 2025-10-08 | Samuelson Doug | grant | 152,672 | — | [4 2025-11-26] |
| 2025-10-08 | Yu John S | grant | 190,840 | — | [4 2025-11-26] |
| 2025-09-16 | Bae Hyun W. | grant | 10,000 | — | [4 2025-12-23] |
| 2025-09-16 | Keyoung Hansoo Michael | grant | 10,000 | — | [4 2025-11-26] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-06 | 8-K | Other events |
| 2026-09-14 | 8-K | Regulation FD disclosure |
| 2026-08-21 | 8-K | Change to security holder rights; Charter, bylaws or fiscal year change; Regulation FD disclosure |
| 2026-08-12 | 10-Q | Quarterly report |
| 2026-07-22 | 8-K | Material agreement entered; Other events |
| 2026-07-15 | 8-K | Other events |
| 2026-06-30 | 8-K | Shareholder vote results |
| 2026-06-04 | 8-K | Other events |
| 2026-05-22 | DEF 14A | Proxy statement |
| 2026-05-18 | 8-K | Other events |
| 2026-05-13 | 10-Q | Quarterly report |
| 2026-05-11 | PRE 14A | Proxy statement |
Alerts for $KAPA
Email me when Kairos Pharma, LTD. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.